Braxia Scientific opens first ketamine therapy clinic in Quebec

Braxia Scientific Corp (CSE:BRAX) (OTCMKTS:SHRMF) (FRA:4960) announced it had opened its first ketamine therapy clinic in Quebec – its fourth centre in Canada.  The clinic, operating under Braxia’s subsidiary Canadian Rapid Treatment Centre of Excellence Inc and doing business as Braxia Health, is the first to offer ketamine therapy in a private clinical setting in the province, the company said in a statement.  The Montreal-based location will be within Braxia’s joint venture partner Neuropathy Montreal Centre’s 14,000 square foot facility.  READ: Braxia Scientific rebrands its psychedelic research and treatment clinics for mental disorders to Braxia Health NMC is staffed with psychiatrists, nurses and other health professionals that treat patients diagnosed with injuries that can lead to major depression and mood disorders, Braxia said, making them prime candidates for ketamine therapy. "We are extremely pleased to be joining Neurotherapy Montreal, expanding our clinical research footprint, but more importantly, having the ability to reach more patients diagnosed with depression and other mental disorders to offer rapid-onset treatments, including Intravenous Ketamine Therapy," Braxia Scientific CEO Dr Roger McIntyre said in a statement. Ketamine therapy Braxia, previously known as Champignon Brands, has administered over 3,000 Intravenous Ketamine Infusions and over 60 Intranasal Ketamine treatments since opening its CRTCE clinics three years ago, according to McIntyre. “Through Braxia Health clinics, these treatments have shown highly significant rapid-acting efficacy to patients with depression. As the first clinic in Canada approved to administer ketamine, and the only community-based centers that administer IV ketamine, many of our patients have experienced substantial relief for what often can be debilitating depression and suicidal thinking." The clinic will be operated as a joint venture, owned equally by Braxia and NMC. The terms of the joint venture are reflected in a binding executed term sheet signed by the parties, but are subject to the execution of a definitive joint venture agreement. Braxia Health, first opened in 2018, is a network of multidisciplinary outpatient clinical research treatment facilities specialized in providing breakthrough rapid-acting treatments for depression using ketamine. Braxia Scientific is a research-driven medical solutions company that aims to treat brain-based mental disorders such as major depressive disorder. Contact Angela at angela@proactiveinvestors.com Follow her on Twitter @AHarmantas